Daniel J George

Angiogenesis , Metastasis , and the Cellular Microenvironment Circulating Tumor Cells from Patients with Advanced Prostate and Breast Cancer Display Both Epithelial and Mesenchymal Markers

Andrew J Armstrong, M. Garcia-Blanco, S. Oltean, 2011 .

Targeted therapy in renal cell carcinoma

J. Favaro, D. George, Daniel J George, 2005, Expert opinion on investigational drugs.

Histone Deacetylase Inhibitor Panobinostat Induces Clinical Responses with Associated Alterations in Gene Expression Profiles in Cutaneous T-Cell Lymphoma

Gordon K Smyth, Joachim Beck, Ricky W Johnstone, 2008, Clinical Cancer Research.

Innovations and Challenges in Renal Cell Carcinoma: Summary Statement from the Second Cambridge Conference

Mark A Rosen, Michael B Atkins, Keith T Flaherty, 2007, Clinical Cancer Research.

Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3.

Oliver Sartor, Susan Halabi, Lawrence H Schwartz, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Response to docetaxel/carboplatin in patients with hormone-refractory prostate cancer not responding to taxane-based chemotherapy.

W. Oh, D. George, Daniel J George, 2005, Clinical prostate cancer.

Development of an integrated prostate cancer research information system.

Beth Katcher, Mark A Rubin, William R Sellers, 2006, Clinical genitourinary cancer.

Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma.

R. Figlin, R. Motzer, M. Michaelson, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.